- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Robert Gabbay Discusses Management of Pediatric Type 1, 2 Diabetes
Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, discusses some of the challenges of treating pediatric patients with type 1 or type 2 diabetes.
The American Diabetes Association (ADA) recognizes that type 2 diabetes in young people is a more severe disease, said Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the ADA.
Transcript
Section 14 of the ADA's 2022 Standards of Medical Care in Diabetes added new information about pediatric type 1 and type 2 diabetes. What is lacking in the care for children?
We recognize that particularly type 2 diabetes in young people is a more severe disease. It progresses more rapidly, and the risk of complications is higher. It's, in essence, a more aggressive disease, and so it's important that clinicians think about how to best manage those individuals and also to screen for them.
Young people with type 1 diabetes continue to be a challenging group and particularly young adults where, if anything, A1C [glycated hemoglobin], not only has it not gotten any better for that population, but it has gotten worse despite all of the technology that's become available. So it was important for us to emphasize the best management about type 1 and type 2 diabetes in children.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
May 13th 2025In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.
Read More
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
May 12th 2025First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
Read More
